CrushSCI.com
159.5Average days
156Median days
44Fastest days
303Longest days
1682025 publications

Paper Review Records

All Paper Review Records

21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

158 days

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context

Authors
Daniele Napolitano; Mattia Bozzetti; Rosario Caruso; Monica Guberti; Ileana Frau; Bobbi Smuck; Gionata Fiorino; Franco Scaldaferri; Lucrezia Laterza; Antonio Gasbarrini; Vincenzina MoraShow moreShow less
Affiliations
1. Scientific Direction – Fondazione Policlinico Universitario IRCCS, Università Cattolica del Sacro Cuore Rome, Rome, Italy; 2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; 3. Direction of Health Professions, ASST Cremona, Cremona, Italy; 4. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; 5. Health Professions Research and Evidence Transfer Unit, IRCCS MultiMedica, Sesto San Giovanni, Italy; 6. Nursing and Allied Health Professions, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; 7. Ass. Prime Site Director, Strategic Site Solutions EMEA - IQVIA, Milan, Italy; 8. Department of Ophthalmology, Ivey Eye Institute, St. Joseph’s Health Care, London, Canada; 9. Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy; 10. Centro Malattie dell’Apparato Digerente (CEMAD), Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, ItalyShow moreShow less
Source PDF DOI Publisher page
210 days

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Authors
Revathi Ananthakrishnan; Patrick Mitchell; Dong Xi; Gu Mi; Gina D’Angelo; Haijun Ma; Yujun Wu; Philip HeShow moreShow less
Affiliations
1. Bristol-Myers Squibb (BMS), Princeton, USA; 2. AstraZeneca (AZ), Gaithersburg, USA; 3. Gilead, Foster City, USA; 4. Sanofi, Cambridge, USA; 5. Revolution Medicines, Redwood City, USA; 6. Oncolytics Biotech Inc, San Diego, USA; 7. Daiichi Sankyo, Inc, Basking Ridge, USAShow moreShow less
Source PDF DOI Publisher page
182 days

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials

Authors
Alexander Przybylski; Björn Holzhauer; Simon WandelShow moreShow less
Affiliations
1. Novartis Pharmaceuticals UK Ltd., London, UK; 2. Novartis Pharma AG, Basel, SwitzerlandShow moreShow less
Source PDF DOI Publisher page
303 days

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China

Authors
Shuxia Shi; Shangyuan Qin; Qin YuShow moreShow less
Affiliations
1. National Drug Clinical Trial Institution of West China Second University Hospital, Sichuan University, Chengdu, China; 2. NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China; 3. Children’s Medicine Key Laboratory of Sichuan Province, Chengdu, China; 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China; 5. Department of Pharmacy, Chengdu Fifth People’s Hospital, Chengdu, ChinaShow moreShow less
Source PDF DOI Publisher page
112 days

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA

Authors
Ling Tang; Songmei Xie; Lijia Yuan; Xiaowen Xu; Xing Ai; Tian Zhao; Zhimin YangShow moreShow less
Affiliations
1. Center for Drug Evaluation, National Medical Products Administration, Beijing, The People’s Republic of ChinaShow moreShow less
Source PDF DOI Publisher page
286 days

Utilization of Clinical Evaluation Reports in Japan’s Medical Device Approvals: Insights from Review Data on Approved Devices

Authors
Koji Yamada; Daisuke Obata; Jun Matsubayashi; Mayumi Yamanaka; Akiko Hinomura; Hiromu Kutsumi; Shin-ya Morita; Shu KasamaShow moreShow less
Affiliations
1. Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan; 2. Asahi Kasei Medical Co., Ltd., Tokyo, Japan; 3. Clinical & Translational Research Center, Kobe University Hospital, Kobe, Japan; 4. Medical Research Support Center, University of Fukui Hospital, Eiheiji-cho, Yoshida-gun, Fukui, Japan; 5. Department of Pharmacotherapeutics, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, JapanShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.